Basic Information
| LncRNA/CircRNA Name | AL161431.1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | endometrial cancer |
| ICD-0-3 | NA |
| Methods | Western blot , luciferase reporter assay etc |
| Sample | EC tissues,cell lines(HEC1-B, KLE, HEC1-A) |
| Expression Pattern | up-regulated |
| Function Description | High expression levels of AL161431.1 were observed in EC patients, tissues, and cells. Loss-of-function experiments validated the carcinogenic role of AL161431.1. Based on the determined cytoplasmic location of AL161431.1, we investigated the ceRNA network and its relation to AL161431.1, miR-1252-5p, and MAPK (mitogen-activated protein kinase) signaling in EC. |
| Pubmed ID | 32196580 |
| Year | 2020 |
| Title | The LncRNA AL161431.1 Targets miR-1252-5p and Facilitates Cellular Proliferation and Migration via MAPK Signaling in Endometrial Carcinoma |
External Links
| Links for AL161431.1 | GenBank HGNC NONCODE |
| Links for endometrial cancer | OMIM COSMIC |